Breaking Down SG&A Expenses: Dr. Reddy's Laboratories Limited vs Jazz Pharmaceuticals plc

SG&A Expenses: Dr. Reddy's vs Jazz Pharmaceuticals

__timestampDr. Reddy's Laboratories LimitedJazz Pharmaceuticals plc
Wednesday, January 1, 201438783000000406114000
Thursday, January 1, 201542585000000449119000
Friday, January 1, 201645702000000502892000
Sunday, January 1, 201746372000000544156000
Monday, January 1, 201846910000000683530000
Tuesday, January 1, 201948890000000736942000
Wednesday, January 1, 202050129000000854233000
Friday, January 1, 2021545590000001451683000
Saturday, January 1, 2022620810000001416967000
Sunday, January 1, 20231059310000001343105000
Monday, January 1, 202477201000000
Loading chart...

Unleashing insights

A Comparative Analysis of SG&A Expenses: Dr. Reddy's vs Jazz Pharmaceuticals

In the competitive landscape of pharmaceuticals, understanding the financial strategies of industry leaders is crucial. Dr. Reddy's Laboratories Limited and Jazz Pharmaceuticals plc, two prominent players, have shown distinct trends in their Selling, General, and Administrative (SG&A) expenses over the past decade. From 2014 to 2023, Dr. Reddy's Laboratories has seen a significant increase in SG&A expenses, peaking in 2023 with a staggering 173% rise from 2014. In contrast, Jazz Pharmaceuticals has maintained a more modest growth, with expenses increasing by approximately 230% over the same period. This divergence highlights Dr. Reddy's aggressive expansion and operational strategies compared to Jazz's more conservative approach. Notably, data for 2024 is incomplete, indicating potential shifts in financial strategies. This analysis provides valuable insights into how these companies allocate resources to maintain their competitive edge.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025